Cognition Therapeutics Inc.

NASDAQ: CGTX
Share price (8/12/25): $1.10
Market cap (8/12/25): $80.8 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/25 Q2

ended 03/31/25 Q1

ended 12/31/24 FY 2024

ended 09/30/24 Q3

ended 06/30/24 Q2

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Registration of securities for employees

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

Caggiano Anthony

Doyle John Brendan

Khattar Jack A.

News Filter

Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs

Shareholder Vote Results

Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia With Lewy Bodies

Investor Presentation

Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC